Zhu Wen-Jing, Yang Shu-di, Qu Chen-Xi, Zhu Qiao-Ling, Chen Wei-Liang, Li Fang, Yuan Zhi-Qiang, Liu Yang, You Ben-Gang, Zhang Xue-Nong
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou.
Department of Clinical Medicine, Nanjing Gulou Hospital, Nanjing, People's Republic of China.
Int J Nanomedicine. 2017 Apr 26;12:3375-3393. doi: 10.2147/IJN.S126310. eCollection 2017.
Multidrug resistance (MDR) is a major obstacle for the clinical therapy of malignant human cancers. The discovery of RNA interference provides efficient gene silencing within tumor cells for reversing MDR. In this study, a new "binary polymer" low-density lipoprotein--succinyl chitosan-cystamine-urocanic acid (LDL-NSC-SS-UA) with dual pH/redox sensitivity and targeting effect was synthesized for the co-delivery of breast cancer resistance protein small interfering RNA (siRNA) and paclitaxel (PTX). In vivo, the co-delivering micelles can accumulate in tumor tissue via the enhanced permeability and retention effect and the specific recognition and combination of LDL and LDL receptor, which is overexpressed on the surface of tumor cell membranes. The siRNA-PTX-loaded micelles inhibited gene and drug release under physiological conditions while promoting fast release in an acid microenvironment or in the presence of glutathione. The micelles escaped from the lysosome through the proton sponge effect. Additionally, the micelles exhibited superior antitumor activity and downregulated the protein and mRNA expression levels of breast cancer resistance protein in MCF-7/Taxol cells. The biodistribution and antitumor studies proved that the siRNA-PTX-loaded micelles possessed prolonged circulation time with a remarkable tumor-targeting effect and effectively inhibited tumor growth. Therefore, the novel dual pH/redox-sensitive polymers co-delivering siRNA and PTX with excellent biocompatibility and effective reversal of MDR demonstrate a considerable potential in cancer therapy.
多药耐药性(MDR)是人类恶性肿瘤临床治疗的主要障碍。RNA干扰的发现为逆转肿瘤细胞中的多药耐药性提供了有效的基因沉默方法。在本研究中,合成了一种具有双重pH/氧化还原敏感性和靶向作用的新型“二元聚合物”低密度脂蛋白-琥珀酰壳聚糖-胱胺-尿刊酸(LDL-NSC-SS-UA),用于共递送乳腺癌耐药蛋白小干扰RNA(siRNA)和紫杉醇(PTX)。在体内,共递送胶束可通过增强的渗透和滞留效应以及LDL与肿瘤细胞膜表面过表达的LDL受体的特异性识别和结合,在肿瘤组织中蓄积。负载siRNA-PTX的胶束在生理条件下抑制基因和药物释放,而在酸性微环境或存在谷胱甘肽的情况下促进快速释放。胶束通过质子海绵效应从溶酶体中逃逸。此外,胶束在MCF-7/紫杉醇细胞中表现出优异的抗肿瘤活性,并下调了乳腺癌耐药蛋白的蛋白质和mRNA表达水平。生物分布和抗肿瘤研究证明,负载siRNA-PTX的胶束具有延长的循环时间,具有显著的肿瘤靶向作用,并有效抑制肿瘤生长。因此,这种新型的双重pH/氧化还原敏感聚合物共递送siRNA和PTX,具有优异的生物相容性和有效的多药耐药性逆转能力,在癌症治疗中显示出巨大的潜力。